Arbitration Tribunal Confirms Ipsen's Termination of Galderma Agreement

On January 21, 2026, the International Chamber of Commerce's Arbitral Tribunal ruled in favor of Ipsen, upholding the termination of its R&D agreement with Galderma. This decision allows Ipsen to retain full rights to its clinical stage toxin programs in the aesthetic field. The outcome highlights and supports Ipsen's strategic focus and advances in neuroscience R&D.

With the arbitration ruling concluded, Ipsen continues to explore opportunities to maximize the value of its innovative IPN10200 molecule. This recombinant combines active and binding sequences to enhance receptor affinity and internalization. It promises a prolonged and clinically significant effect, undergoing evaluation in four Phase II trials for aesthetic and therapeutic uses.